文献速递免疫规划传染病防控与疫情报告

COVID-19疫苗接种与急性神经事件的安全性:基于OpenSAFELY平台的英格兰自控病例系列研究

Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform.
PubMed 文献 · Vaccine · 2022-06-07

发现首剂ChAdOx1疫苗后吉兰-巴雷综合征和贝尔麻痹发生率短期升高,绝对风险低;BNT162b2和mRNA-1273未显示明确关联。

要点

  • 首剂ChAdOx1疫苗后吉兰-巴雷综合征发生率升高(发生率比2.85,95%CI 2.33-3.47),第二剂无此现象。
  • 首剂ChAdOx1疫苗后贝尔麻痹发生率升高(发生率比1.39,95%CI 1.27-1.53)。
  • BNT162b2和mRNA-1273疫苗未显示与所研究急性神经事件的明确关联。

核心结论

  • 观察到的首剂ChAdOx1疫苗后吉兰-巴雷综合征和贝尔麻痹发生率短期升高,假设归因于疫苗接种的绝对风险较低。

研究设计与样本

  • 采用自控病例系列设计,按疫苗品牌分别估计接种后风险期(吉兰-巴雷综合征4-42天,横贯性脊髓炎和贝尔麻痹4-28天)相对于个体基线期的事件发生率比,使用条件泊松回归。

主要发现

  • ChAdOx1疫苗接种与横贯性脊髓炎无明确关联证据(N=199;发生率比1.51,95%CI 0.96-2.37)。
  • 5,729,152名BNT162b2接种者中,与吉兰-巴雷综合征(N=283;发生率比1.09,95%CI 0.75-1.57)、横贯性脊髓炎(N=109;发生率比1.62,95%CI 0.86-3.03)或贝尔麻痹(N=3,609;发生率比0.89,95%CI 0.76-1.03)均无关联证据。
  • 255,446名mRNA-1273接种者中,与贝尔麻痹无关联证据(N=78;发生率比0.88,95%CI 0.32-2.42)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We investigated the potential association of COVID-19 vaccination with three acute neurological events: Guillain-Barré syndrome (GBS), transverse myelitis and Bell's palsy. METHODS: With the approval of NHS England we analysed primary care data from >17 million patients in England linked to emergency care, hospital admission and mortality records in the OpenSAFELY platform. Separately for each vaccine brand, we used a self-controlled case series design to estimate the incidence rate ratio for each outcome in the period following vaccination (4-42 days for GBS, 4-28 days for transverse myelitis and Bell's palsy) compared to a within-person baseline, using conditional Poisson regression. RESULTS: Among 7,783,441 ChAdOx1 vaccinees, there was an increased rate of GBS (N = 517; incidence rate ratio 2·85; 95% CI2·33-3·47) and Bell's palsy (N = 5,350; 1·39; 1·27-1·53) following a first dose of ChAdOx1 vaccine, corresponding to 11.0 additional cases of GBS and 17.9 cases of Bell's palsy per 1 million vaccinees if causal. For GBS this applied to the first, but not the second, dose. There was no clear evidence of an association of ChAdOx1 vaccination with transverse myelitis (N = 199; 1·51; 0·96-2·37). Among 5,729,152 BNT162b2 vaccinees, there was no evidence of any association with GBS (N = 283; 1·09; 0·75-1·57), transverse myelitis (N = 109; 1·62; 0·86-3·03) or Bell's palsy (N = 3,609; 0·89; 0·76-1·03). Among 255,446 mRNA-1273 vaccine recipients there was no evidence of an association with Bell's palsy (N = 78; 0·88, 0·32-2·42). CONCLUSIONS: COVID-19 vaccines save lives, but it is important to understand rare adverse events. We observed a short-term increased rate of Guillain-Barré syndrome and Bell's palsy after first dose of ChAdOx1 vaccine. The absolute risk, assuming a causal effect attributable to vaccination, was low.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Walker JL, Schultze A, Tazare J, et al. Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform. Vaccine. 2022. PMID: 35715350. doi:10.1016/j.vaccine.2022.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。